5/5/2023 0 Comments Jeff brown bleeding edge covid![]() Overall the number of thromboembolic events reported after vaccination, both in studies before licensing and in reports after rollout of vaccination campaigns (469 reports, 191 of them from the EEA), was lower than that expected in the general population. The PRAC involved experts in blood disorders in its review, and worked closely with other health authorities including the UK’s MHRA which has experience with administration of this vaccine to around 11 million people. A causal link with the vaccine is not proven, but is possible and deserves further analysis. ![]() These are rare cases – around 20 million people in the UK and EEA had received the vaccine as of March 16 and EMA had reviewed only 7 cases of blood clots in multiple blood vessels (disseminated intravascular coagulation, DIC) and 18 cases of CVST. low levels of blood platelets (elements in the blood that help it to clot) with or without bleeding, including rare cases of clots in the vessels draining blood from the brain (CVST). however, the vaccine may be associated with very rare cases of blood clots associated with thrombocytopenia, i.e.there is no evidence of a problem related to specific batches of the vaccine or to particular manufacturing sites.the vaccine is not associated with an increase in the overall risk of blood clots (thromboembolic events) in those who receive it.the benefits of the vaccine in combating the still widespread threat of COVID-19 (which itself results in clotting problems and may be fatal) continue to outweigh the risk of side effects. ![]() EMA’s safety committee, PRAC, concluded its preliminary review of a signal of blood clots in people vaccinated with Vaxzevria (previously COVID-19 Vaccine AstraZeneca) at its extraordinary meeting of 18 March 2021. ![]()
0 Comments
Leave a Reply. |